Recombinant CEACAM6 (Tinurilimab Biosimilar) antibody
Quick Overview for Recombinant CEACAM6 (Tinurilimab Biosimilar) antibody (ABIN7581328)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab)
-
Sequence
- QVTLRESGPA LVKPTQTLTL TCTFSGFSLS TYGIGVGWIR QPPGKALEWL AHIWWNDNKY YSTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI SLPYFDYWGQ GTTLTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPG,DIQLTQSPSF LSASVGDRVT ITCKASQNVG TAVAWYQQKP GKAPKLLIYS ASNRYTGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCQQ YSSYPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Characteristics
- Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG2SA
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: CEACAM6 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- CEACAM6 (Tinurilimab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- P40199
Target
-